Agreed, commentary was good though.
"Development continues on the Uscom BP+ in preparation for global volume marketing. The China regulatory approval is under way for the BP+ which will lead to initiation of the China Pioneer distribution deal, which is contracted to deliver an average $1.4m US revenue per annum over each of the next 5 years to Uscom."
So China regulatory approval would be the big catalyst.
More than doubling revenue. With the aquisition, this should likely make them profitable.
Anyone know when approval may be?
- Forums
- ASX - By Stock
- UCM
- Ann: Appendix 4C - quarterly
Ann: Appendix 4C - quarterly, page-4
-
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add UCM (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.506M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 3.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.0¢ | 66058 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 12000 | 0.170 |
1 | 100000 | 0.155 |
1 | 200000 | 0.150 |
1 | 100000 | 0.130 |
1 | 6061 | 0.125 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 40162 | 2 |
0.190 | 19474 | 1 |
0.200 | 49094 | 1 |
0.220 | 22727 | 1 |
0.240 | 256024 | 1 |
Last trade - 16.12pm 25/11/2024 (20 minute delay) ? |
Featured News
UCM (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online